Health and Healthcare
Bioject's Needle-Free Delivery Technology Used by NIH
Published:
From BioHealth Investor
Bioject Medical Technologies Inc (BJCT) announced early Thursday that the National Institutues of Health (NIH) has initiated its DNA vaccine study to prevent the H5N1 flu virus using the company’s needl-free technology, Biojector 2000 (B2000).
The study aims to use the B2000 to deliver an experimental vaccine by a high pressure liquid forced through the skin, thus ensuring the comfort and safety of the test subjects and investigators.
45 total volunteers will take part in the study, 30 of whom will receive the vaccine, while the rest will receive a placebo injection.
Bioject is a very tiny company, worth slightly less than $15 on the market. It caries about $3 million in cash, and carries debts of about $900 thousand.
Revenues have been increasing steadily over the last few years, but the company’s bottom line has yet to catch up.
Shares of Bioject closed at a penny above $1 on Wednesday, with a 52-week range of $0.72 to $2.
http://www.biohealthinvestor.com/
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
